Weight loss OTC diet pill Alli works with regular physical activity, exercise and good food with low calorie diet. The first and only over-the-counter product for weight loss approved by the Food and Drug Administration is available in US now.
Adding Glaxo’s Alli to diet and exercise can help people lose 50 per cent more weight than with dieting alone. This first U.S. sanctioned diet drug to be sold without a prescription is proving wildly popular.
Alli is the only FDA-approved weight-loss product available to overweight adults, 18 years or older, without a prescription. It combines a clinically-proven product with a comprehensive individualized action plan.
Obesity, high blood pressure, high cholesterol, and inactivity: they?re not just your father?s problems any more, University of New Hampshire research finds. New data on the widely unstudied demographic of college students indicates that this group of 18 ? 24-year-olds are on the path toward chronic health diseases. Although limited, national data suggest the trend is not unique to UNH.
A study conducted in a large sample of postmenopausal women by University at Buffalo epidemiologists has provided new information on the prevalence of certain gum-disease-causing oral bacteria in this population and the association of the bacteria with oral bone loss.
Add foot problems to the long list of conditions that being overweight can cause or exacerbate, says Foot Care Basics: Preventing and treating common foot conditions, a newly updated report from Harvard Medical School.
An Oprah Winfrey-inspired study done by researchers at the Stanford University School of Medicine has found that patients who undergo gastric bypass surgery to lose weight will get drunk faster and take longer to get sober.
The global obesity epidemic was issued with a further health warning today — that obesity exacerbates the quality of life of patients with rheumatoid arthritis. New data presented at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain, shows that RA in obese patients is associated with worse quality of life outcomes on four key levels: pain, fatigue, physical function and overall utility scores.
Diabetes is often called a lifestyle disease, and now a new study from the University of Missouri-Columbia verifies that a lifestyle change brings strong improvements.
Sanofi-aventis announced that the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee did not recommend approval of rimonabant (ZIMULTI(R)) to the US FDA for use in obese and overweight patients with associated risks factors.